OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
LIPC variant in combined hypocholesterolaemia	956
Antibody treatment to deplete transthyretin amyloid deposits in the heart	471
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	469
Intravascular imaging improves outcomes	423
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	412
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	407
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	401
The City Heartbeat Index as a benchmarking tool for urban cardiovascular health	375
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	319
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	308
Takotsubo syndrome: pathophysiological insights and innovations in patient care	307
Optimizing cardiovascular pharmacotherapy in older adults with frailty	306
Genetics and mechanisms of thoracic aortic disease	297
Alternative defibrillation strategies improve outcomes	270
Think Aorta: aortic dissection awareness and perspectives from the patient	260
Detection of subclinical hypertrophic cardiomyopathy	247
Base editing and silencing of PCSK9 shows clinical promise in humans	236
Drug-coated balloon angioplasty for coronary and peripheral artery disease: latest evidence and clinical indications	235
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	235
Defining iron deficiency in patients with heart failure	231
HFpEF and MASLD: converging mechanisms and clinical implications	229
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	229
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	211
Hallmarks of cardiovascular ageing	209
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	198

Preparticipation screening reduces SCD in young athletes	171
LDL-cholesterol lowering with obicetrapib	163
No benefit of apoA-I infusion after myocardial infarction	162
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	157
Catheter ablation improves outcomes in patients with AF and end-stage HF	150
Colchicine in acute coronary syndromes: the present and the possible future	149
Increased degradation of desmosomal proteins in ACM	142
CSDE1 regulates LDL receptor levels	138
Tailored therapeutics for cardiomyopathies	135
Extracellular matrix in vascular homeostasis and disease	132
Targeting immune cell recruitment in atherosclerosis	132
Graded exercise therapy should not be recommended for patients with post-exertional malaise	128
Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes	128
Cardiac lymphatic dysfunction and repair in cardiovascular disease	128
Decongestion in heart failure: medical and device therapies	122
Reactive oxygen species in hypertension	118
Donor macrophages influence rejection of transplanted hearts	115
The oral microbiome in the pathophysiology of cardiovascular disease	115
Modelling pre-eclampsia and its cardiovascular effects	114
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	112
Cardiac sarcomere turnover by unidirectional replacement of proteins	110
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	109
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	109
Promising novel siRNA for the treatment of hypertension	108
Semaglutide is beneficial in patients with HFpEF and obesity	106
Calculation methods for LDL cholesterol are evolving tools for accuracy in lipidology	103
Evidence does not support the reduction of added sugar intake from all food sources	101
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	99
RNA interference lowers triglyceride levels	99
Local calcium dynamics and signalling in cardiomyocytes	98
Global epidemiology of heart failure	97
An epigenome editing approach induces durable silencing of Pcsk9	95
Single-cell profiles of CHD and CM	91
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	88
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	86
The role of the molecular autopsy in sudden cardiac death in young individuals	83
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	80
Development of a miniature, bioresorbable, light-activated pacemaker	78
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	76
Digital screening and decision-support tools in equitable preventive cardiology	73
Heart transplantation: advances in expanding the donor pool and xenotransplantation	73
Tricuspid valve disease: updates on diagnostic imaging and intervention	72
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	71
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	70
Efferocytosis in atherosclerosis	70
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	68
Baxdrostat beneficial in uncontrolled or resistant hypertension	67
PCSK9 inhibition for primary prevention of cardiovascular events	66
Gut bacteria can break down cholesterol	63
Gene–environment interactions in the pathogenesis of cardiovascular disease	63

New insights into dietary cholesterol absorption	61
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	59
Improving medication adherence in cardiovascular disease	58
Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation	58
Mechanisms and treatment of pulmonary arterial hypertension	57
Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis	55
Cardiovascular benefits of fermented foods and beverages: still up for debate	55
Stenting for post-thrombotic syndrome	55
Cardiovascular disease and cancer: shared risk factors and mechanisms	50
Renal denervation for hypertension	48
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	48
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	45
Cardiac optogenetics: controlling the heart with light	44
Transcriptional regulation in heart development, disease and regeneration: reassessing the fetal gene hypothesis	43
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	42
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	41
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	41
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	41
Integration of cardiovascular and mental health: from concepts to the clinic	40
Synthetic ion channel modulator reverses sodium channel dysfunction linked to cardiac arrhythmias	40
Heart failure and obesity: novel insights leading to new treatment paradigms	40
Epigenetic editing in cardiovascular medicine: moving beyond the hype	39
The environmental exposome in heart failure risk and progression	38
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	38
The cardiac parasympathetic system has two parallel circuits	37
Metabolites matter for gut microbiota as a modifiable risk factor in cardiovascular diseases	37
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	36
Black In Cardio: promoting diversity and representation in the cardiovascular field	36
Gout flares can precede cardiovascular events	35
Sotatercept as add-on therapy for advanced PAH	33
Colchicine in patients with cardiovascular disease	33
Inhibiting aldosterone synthase reduces blood pressure	33
ASGR1 inhibition stimulates cholesterol excretion	32
Phase separation of protein kinase A: a new paradigm in cardiac regulation?	32
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	32
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	31
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	31
Age-induced senescence impairs the neurovascular interface in the heart	31
Consequences of ionizing radiation exposure to the cardiovascular system	30
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	30
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	29
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	29
Surgery safer than endovascular therapy for CLTI	28
Artificial intelligence-enhanced echocardiography in cardiovascular disease management	28
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes	28
A distinct platelet differentiation pathway is involved in age-related thrombocytosis	27
Characterization of the F8 gene: a silver lining in a dark cloud	27
Preserving the future of heart transplantation	27
Genome editing prevents hypertrophic cardiomyopathy in mice	26
Building the Australian Cardiovascular disease Data Commons	26
An ex vivo perfusion platform for the testing of cardiovascular interventional devices	25
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies	25
Leadless and extravascular cardiac resynchronization therapy: the future for CRT?	25
Vagal mechanoreceptors in the heart sense changes in blood volume	24
Epidemiology of non-ischaemic dilated cardiomyopathy	24
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	24
A role for lipophagy in atherosclerosis	24
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	24
Mind the gap: sex-related differences in cardiovascular disease	23
Implementing LGBTQ-inclusive policies for cardiology practice and the workforce	23
Unravelling the genetic heart–brain connection using MRI	23
Alain Cribier (1945–2024)	23
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity	22
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease	21
Single-cell transcriptomics for the assessment of cardiac disease	21
Cardiac epigenome in heart development and disease	21
Non-coding RNAs in lipid metabolism and their roles in atherosclerosis	19
The ongoing quest for the first total artificial heart as destination therapy	19
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group	18
Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy	18
Charting the future of cardiology with large language model artificial intelligence	18